268 related articles for article (PubMed ID: 32615710)
1. Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus.
Jung CH; Mok JO
Endocrinol Metab (Seoul); 2020 Jun; 35(2):260-271. PubMed ID: 32615710
[TBL] [Abstract][Full Text] [Related]
2. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
Hupfeld C; Mudaliar S
Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
4. Subclinical macroangiopathic target organ damage in type 1 diabetes mellitus patients.
Błaszkowska M; Shalimova A; Wolnik B; Orłowska-Kunikowska E; Graff B; Hoffmann M; Nilsson P; Wolf J; Narkiewicz K
Blood Press; 2020 Dec; 29(6):344-356. PubMed ID: 32460564
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus-Part 1.
Yandrapalli S; Jolly G; Horblitt A; Pemmasani G; Sanaani A; Aronow WS; Frishman WH
Cardiol Rev; 2020; 28(4):177-189. PubMed ID: 32282393
[TBL] [Abstract][Full Text] [Related]
6. Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes.
Yun JS; Ko SH
Metabolism; 2021 Oct; 123():154838. PubMed ID: 34333002
[TBL] [Abstract][Full Text] [Related]
7. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
8. Myocardial dysfunction and cardiovascular disease in type 2 diabetes.
Ofstad AP
Scand J Clin Lab Invest; 2016 Jul; 76(4):271-81. PubMed ID: 27071642
[TBL] [Abstract][Full Text] [Related]
9. Crossing family histories of diabetes and cardiovascular disease leads to unexpected outcomes in diabetic offspring.
Hermans MP; Ahn SA; Rousseau MF
J Diabetes; 2019 Apr; 11(4):301-308. PubMed ID: 30105804
[TBL] [Abstract][Full Text] [Related]
10. Maximum carotid intima-media thickness improves the prediction ability of coronary artery stenosis in type 2 diabetic patients without history of coronary artery disease.
Irie Y; Katakami N; Kaneto H; Kasami R; Sumitsuji S; Yamasaki K; Tachibana K; Kuroda T; Sakamoto K; Umayahara Y; Ueda Y; Kosugi K; Shimomura I
Atherosclerosis; 2012 Apr; 221(2):438-44. PubMed ID: 22321873
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive cardiac imaging techniques and vascular tools for the assessment of cardiovascular disease in type 2 diabetes mellitus.
Djaberi R; Beishuizen ED; Pereira AM; Rabelink TJ; Smit JW; Tamsma JT; Huisman MV; Jukema JW
Diabetologia; 2008 Sep; 51(9):1581-93. PubMed ID: 18607561
[TBL] [Abstract][Full Text] [Related]
12. Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.
Santamarina M; Carlson CJ
BMC Cardiovasc Disord; 2019 Mar; 19(1):60. PubMed ID: 30876392
[TBL] [Abstract][Full Text] [Related]
13. Cohort comparison study of cardiac disease and atherosclerotic burden in type 2 diabetic adults using whole body cardiovascular magnetic resonance imaging.
Duce SL; Weir-McCall JR; Gandy SJ; Matthew SZ; Cassidy DB; McCormick L; Rauchhaus P; Looker H; Colhoun HM; Houston JG
Cardiovasc Diabetol; 2015 Sep; 14():122. PubMed ID: 26382729
[TBL] [Abstract][Full Text] [Related]
14. Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus.
Cherney DZI; Repetto E; Wheeler DC; Arnold SV; MacLachlan S; Hunt PR; Chen H; Vora J; Kosiborod M
Am J Nephrol; 2020; 51(1):74-82. PubMed ID: 31812955
[TBL] [Abstract][Full Text] [Related]
15. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
Pancholia AK
Indian Heart J; 2018; 70(6):915-921. PubMed ID: 30580866
[TBL] [Abstract][Full Text] [Related]
17. SOX6 gene polymorphism (rs16933090) and markers of subclinical atherosclerosis in patients with type 2 diabetes mellitus.
Pleskovič A; Šantl Letonja M; Cokan Vujkovac A; Kruzliak P; Petrovič D
Int Angiol; 2016 Dec; 35(6):552-556. PubMed ID: 26868133
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Paneni F; Lüscher TF
Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
[TBL] [Abstract][Full Text] [Related]
19. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
Dailey G
Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
[TBL] [Abstract][Full Text] [Related]
20. Qualitative score of systemic arteriosclerosis by vascular ultrasonography as a predictor of coronary artery disease in type 2 diabetes.
Hirata A; Kishida K; Hiuge-Shimizu A; Nakatsuji H; Funahashi T; Shimomura I
Atherosclerosis; 2011 Dec; 219(2):623-9. PubMed ID: 21930272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
